AstraZeneca PLC has signed two new outcomes-based reimbursement contracts with Harvard Pilgrim Health Care for the blood thinner Brilinta (tocagrelor) and the diabetes drug Bydureon (exenatide extended release), bringing the total number of the company's value-based reimbursement contracts to 13.
The double-digit number represents a significant amount of contracts in what is an exploratory area for the industry, as pharma manufacturers and insurers attempt better align the cost of medicines...